CTOs on the Move

Eversana

www.eversana.com

 
EVERSANA™ is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion
  • www.eversana.com
  • 190 North Milwaukee Street
    Milwaukee, WI USA 53202
  • Phone: 414.299.4900

Executives

Name Title Contact Details
Ryan Sparks
Chief Information Officer Profile
Mark Henke
Chief Information Security Officer Profile
Scott Snyder
Chief Digital Officer Profile

Similar Companies

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a Westfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neotropix

Neotropix is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spence Pharmacy and Medical Supl

Spence Pharmacy and Medical Supl is a River Oaks, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Therigy

Therigy® is a patient-focused specialty therapy management company. As an industry pioneer, Therigy continues to lead the specialty pharmacy market as the top choice in technology and consulting solutions—with the best possible outcomes for patients in mind.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.